From: Immunotherapy for Alzheimer’s disease: targeting β-amyloid and beyond
Therapeutic strategy | Drug | Mechanism | Sponsor | Study population | Admin | Phase | Results | Clinical Trial Identifier | Start date | Estimated end date |
---|---|---|---|---|---|---|---|---|---|---|
Active immunotherapy | AN1792 | Vaccination | Janssen/Pfizer | Mild to moderate AD | IM | II | Terminated | NCT00021723 | 2001 Sept | 2003 Sept |
Amilomotide (CAD106) | Vaccination | Novartis | Participants at risk of the onset of clinical symptoms of AD | IM | II/III | Terminated | NCT02565511 | 2015 Nov | 2020 Apr | |
UB-311 | Vaccination | United Neuro-science | Mild AD | IM | II | Completed | NCT02551809 | 2015 Oct | 2018 Aug | |
Mild AD | II | Terminated | NCT03531710 | 2018 Aug | 2019 Oct | |||||
ABvac40 | Vaccination | Araclon Biotech | Participants with amnestic mild cognitive impairment or very mild AD | SC | II | Active, not recruiting | NCT03461276 | 2018 Feb | 2022 Dec | |
Passive immunotherapy | Solanezumab (LY2062430) | Monoclonal antibody | Eli Lilly | Mild to moderate AD | IV | III | Completed | NCT00905372 | 2009 May | 2012 Apr |
Mild to moderate AD | Completed | NCT00904683 | 2009 May | 2012 Jun | ||||||
Mild to moderate AD | Terminated | NCT01127633 | 2010 Dec | 2017 Feb | ||||||
Mild AD | III | Terminated | NCT01900665 | 2013 Jul | 2016 Oct | |||||
Prodromal AD | III | Terminated | NCT02760602 | 2016 Jun | 2017 May | |||||
Participants at risk of memory loss | III | Active, not recruiting | NCT02008357 | 2014 Feb | 2022 Dec | |||||
Gantenerumab | Monoclonal antibody | Roche | Prodromal AD | IV | Completed | NCT01224106 | 2010 Nov | 2020 Sept | ||
Mild AD | Completed | NCT02051608 | 2014 Mar | 2021 Apr | ||||||
Prodromal to mild AD | Recruiting | NCT04374253 | 2014 Mar | 2021 Apr | ||||||
Early AD | Recruiting | NCT03444870 | 2018 Jun | 2023 Nov | ||||||
Early AD | Active, not recruiting | NCT03443973 | 2018 Aug | 2022 Sept | ||||||
Early AD | Active, not recruiting | NCT04339413 | 2020 May | 2023 Apr | ||||||
Aducanumab (BIIB037) | Monoclonal antibody | Biogen | Early AD | IV | III | Terminated | NCT02484547 | 2015 Sept | 2019 Aug | |
Early AD | III | Terminated | NCT02477800 | 2015 Aug | 2019 Aug | |||||
Early AD | III | Active, not recruiting | NCT04241068 | 2020 Mar | 2023 Oct | |||||
Crenezumab (RG7412) | Monoclonal antibody | Roche/AC Immune SA | Prodromal to mild AD | IV | III | Terminated | NCT02670083 | 2016 Mar | 2019 May | |
Prodromal to mild AD | III | Terminated | NCT03114657 | 2017 Mar | 2019 Jun | |||||
Prodromal to mild AD | III | Terminated | NCT03491150 | 2018 Apr | 2019 May | |||||
Lecanemab (BAN2401) | Monoclonal antibody | Biogen /Eisai | Early AD | IV | III | Recruiting | NCT03887455 | 2019 Mar | 2024 Aug | |
Preclinical AD | III | Recruiting | NCT04468659 | 2020 Jul | 2027 Oct | |||||
Donanemab (LY3002813) | Monoclonal antibody | Eli Lilly | Early symptomatic AD | IV | III | Recruiting | NCT04437511 | 2020 Jun | 2023 Dec | |
Preclinical AD | III | Recruiting | NCT05026866 | 2021 Aug | 2027 Sept |